GlassScriptPhysician profile
Cory E Rathgeber
NPI 1649367343
$6,917.66
in general payments reported to CMS, 2019-2025
39 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $886 · 2021: $829 · 2022: $901 · 2023: $969 · 2024: $1,307 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,092.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $842.24 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $691.69 | 2020-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $662.79 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.31 | 2019-2024 | Jardiance, Tradjenta |
| Pfizer INC. | $557.92 | 2019-2025 | |
| Novo Nordisk INC | $423.56 | 2019-2024 | |
| Lundbeck LLC | $348.16 | 2020-2024 | Rexulti |
| Astellas Pharma US INC | $327.48 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $308.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $300.28 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $264.39 | 2019-2025 | |
| Abbott Laboratories | $232.97 | 2021-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $169.91 | 2020-2025 | Eliquis, Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.78 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $118.12 | 2022-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Rathgeber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.